HKSE - Delayed Quote HKD

IMMUNEONCO-B (1541.HK)

6.140

+0.120

(+1.99%)

At close: 4:08:20 PM GMT+8

Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Licensed SYN-2510, a potential best-in-class PD-L1xVEGF bispecific antibody, for global ex-China development and commercialization Clinical data update for SYN-2510/IMM2510 in China from ImmuneOnco anticipated in 1H 2025 Initiation of Phase 1b/2 SYN-2510/IMM2510 + chemotherapy combination in first-line non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC) anticipated in late 2024 and 1H 2025, respectively, by ImmuneOnco in China U.S. clinical study of SYN-2510/IMM2510 in NS

GlobeNewswire last month

1541.HK
+1.99%
TIL
Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer

Global registrational strategy in first-line non-squamous and squamous non-small cell lung cancer (NSCLC)Global registrational strategy in first-line triple-negative breast cancer (TNBC)Initiation of Phase 1b/2 IMM2510/SYN-2510 + chemotherapy combination in first-line NSCLC anticipated in late 2024 in ChinaInitiation of Phase 1b/2 IMM2510/SYN-2510 + chemotherapy combination in first-line TNBC anticipated in early 2025 in ChinaUS IND submission for SYN-2510 targeted in late 2024, starting with Ph

GlobeNewswire 2 months ago

TIL

1541.HK
+1.99%
Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody

DALLAS and SHANGHAI, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, “Instil”) and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, “ImmuneOnco”), today announced a definitive agreement pursuant to which Instil is in-licensing ex-China development and commercial rights to ImmueOnco’s proprietary PD-L1xVEGF bispecific antibody, IMM2510, as well as its next-generation anti-CTLA-4 antibody, IMM27M. IMM2510 is a novel, potentially best-in-class bispecific antibody

GlobeNewswire 4 months ago

TIL

1541.HK
+1.99%

Performance Overview

Return	1541.HK	HANG SENG INDEX
YTD	-79.46%	+16.12%
1-Year	-79.12%	+17.89%
3-Year	-71.04%	-15.48%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

IMMUNEONCO-B (1541.HK)

Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer

Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody

Performance Overview